InterVenn Receives AMA PLA Code for Non-Invasive Ovarian Cancer Diagnostic

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, today announced that its flagship test, GlycoKnow™ Ovarian, has received a Proprietary Laboratory Analysis (PLA) code from the American Medical Association (AMA). GlycoKnow Ovarian is a blood-based liquid biopsy diagnostic that helps distinguish ovarian cancer from benign pelvic masses, enabling women to receive the most appropriate care as quickly as possible. The test will be commercially available this fall, aligned with the coding effective date of October 1, 2025.